Merck & Co. closed a global licensing agreement with China-based SciBrunch Therapeutics for a preclinical oral KRAS G12D (on) inhibitor. The deal includes $400 million upfront and additional development and commercialization payments tied to milestones across multiple indications, placing another company’s pipeline behind the KRAS G12D oncology driver that has attracted sustained M&A and licensing interest.